← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Virogenics, Inc.
Del Mar, CA
$21,643,754
Total funding
14
Grants
Funding over time
peak $4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,643,754 · 14
By mechanism
R44$8,013,707 · 3
R01$5,303,779 · 1
U01$3,156,836 · 1
R43$2,797,997 · 6
R42$1,499,999 · 1
R41$599,936 · 1
Investigators at Virogenics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease$2,503,169
R01 · FY2021 · AG
Paving the Way to Phase 2 Trials of CMS121 for Alzheimer's Disease$2,432,649
R44 · FY2024 · AG
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease$2,338,814
R01 · FY2022 · AG
Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for AD$1,594,649
U01 · FY2024 · AG
Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for AD$1,562,187
U01 · FY2025 · AG
FIV Vectors for the Treatment of Hemophilia A$1,009,436
R44 · FY2011 · HL
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD$977,956
R44 · FY2018 · AI
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD$967,956
R44 · FY2019 · AI
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD$965,711
R44 · FY2020 · AI
FIV Vectors for the Treatment of Hemophilia A$905,804
R44 · FY2010 · HL
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD$771,449
R42 · FY2016 · AI
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD$728,550
R42 · FY2017 · AI
FIV Vectors for the Treatment of Hemophilia A$699,475
R44 · FY2012 · HL
Lentiviral Vector Gene Therapy for CD45 Deliver$374,400
R43 · FY2003 · AI
Lentiviral Vector Gene Therapy for CD45 Deliver$374,400
R43 · FY2004 · AI
Non-Integrating FIV Vectors for HIV Vaccines$300,002
R43 · FY2006 · AI
Non-Integrating FIV Vectors for HIV Vaccines$300,000
R43 · FY2007 · AI
siRNA Modulation of the Immune Response$300,000
R43 · FY2013 · AI
siRNA Modulation of the Immune Response$300,000
R43 · FY2014 · AI
Modulation of the Innate Immune System by Fisetin for the Treatment of AD$299,968
R41 · FY2014 · AI